Healthcare / Medical Instruments & SuppliesBSE
$86.30
+0.10 (+0.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $11.3M · quality 35.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$315M
P/E
N/A
•EV/EBITDA
13.4x
↑ROE
-4.8%
↓Gross Margin
67.1%
↑Debt/Equity
1.09
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.4%
FCF CAGR
+6.9%
FCF margin
10.5%
FCF / Net income
-3.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $535.2M · net income $-14.6M · FCF $56.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $535.2M | $535.2M | $511.9M | $526.6M | $444.3M |
| Net Income | $-14.6M | $-14.6M | $11.3M | $8.9M | $6.3M |
| EBITDA | $48.2M | $48.2M | $35.9M | $34.6M | $33.7M |
| EPS | -4.01 | -4.01 | 3.11 | 2.43 | 1.72 |
| Gross Margin | 67.1% | 67.1% | 66.2% | 61.6% | 55.4% |
| Operating Margin | 3.8% | 3.8% | 7.4% | 5.9% | 6.7% |
| Net Margin | -2.7% | -2.7% | 2.2% | 1.7% | 1.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.09 | 1.09 | 0.86 | 0.48 | 0.49 |
| Cash Flow | |||||
| Free Cash Flow | $56.0M | $56.0M | $-14.8M | $11.3M | $45.9M |
| Returns | |||||
| ROE | -4.8% | -4.8% | 3.5% | 2.9% | 2.1% |
| Valuation | |||||
| EV/EBITDA | 13.43 | 13.43 | — | — | — |
| P/B | 1.02 | 1.02 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 4.5% | 4.5% | -2.8% | 18.5% | — |
| EPS Growth | -228.9% | -228.9% | 28.0% | 41.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.8%
Start / end P/E
n/dx → n/dx
EPS bridge
3.11 → -4.01
Residual
-29.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.